On 19 November 2020, the CJEU delivered a founding judgment in case C-663/18, better known as Kanavape. It tipped French CBD from a grey zone into a stabilised legal framework.

The case in brief

Two managers of a French startup, Kanavape, sold CBD vape cartridges in 2014 using extract from legally grown Czech hemp. French courts initially convicted them under narcotics law — France at the time banning extraction from flowers and leaves, even from legal European hemp.

The Aix-en-Provence appeal court referred the matter to the CJEU as a preliminary question: was France's stance compatible with EU law?

The Court's reasoning

CBD is not listed in the 1961 Single Convention on narcotic drugs. Current science does not show psychoactive harm comparable to THC. Free movement of goods (TFEU articles 34 and 36) applies: a member state cannot ban a product legally made in another member state without proving a real public health risk based on solid science. France did not provide that evidence, so the ban was disproportionate.

Immediate consequences

• CBD oils and e-liquids extracted from flowers and leaves became sellable in France if legally produced in the EU.
• The 1990 French decree restricting extraction to seeds and stems lost its legal basis.
• France had to reshape its framework — leading to the 30 December 2021 decree.
• Operators whose stock had been seized between 2014 and 2020 obtained, in several cases, post-hoc acquittals on appeal.
• Investment in the French CBD industry effectively restarted after years of cautious wait-and-see.

Structural effect on the market

Beyond Kanavape itself, the ruling triggered a cascade. Carriers, previously reluctant to handle CBD parcels, aligned their general conditions. Banks, after years of closing CBD professional accounts, reopened — not without friction, but with a more predictable framework. Insurers eventually offered liability contracts tailored to CBD trade. None of this ecosystem would have held without the legal stability the ruling brought.

The ruling's limits

Kanavape is not absolute. A state may still restrict CBD trade if it proves a real health risk. This is the basis for ANSM bans on semi-synthetics (HHC, H4CBD) and the ongoing novel food file on supplements.

Outside the EU?

Kanavape only covers products made in an EU member state. CBD from the US, Switzerland or post-Brexit UK falls under separate import rules.

Five years on: what really changed

In hindsight, Kanavape set three milestones that practice has consolidated. First, a shift from pure prohibition to regulation. Second, certificates of analysis became the central probative piece in any inspection. Third, hemp gained recognition as a legitimate agricultural and industrial sector, with trade unions, professional bodies and quality standards. The market structured its practices: supplier audits, lab audits, label compliance, sales training. None of those standards would have a reason to exist without Kanavape.

The Horus stance

We source exclusively from EU growers and processors. It is the simplest way to rely on Kanavape free movement without uncertainty. This short supply chain also helps traceability — documented at our Boulogne-sur-Gesse and L'Isle-en-Dodon shops.

Further reading: CBD legal framework in France 2026.

This article is for informational purposes only. For legal advice, consult a lawyer. CBD is not a medicine.